ONWARD Medical Raises €40.6M to Fuel Spinal Cord Injury Therapies
Event summary
- ONWARD Medical raised €40.6M via accelerated bookbuild offering of 13.5M new shares at €3.00 per share.
- EQT Life Sciences invested €25.0M, with additional support from high-quality, long-only investors.
- Proceeds will extend cash runway into Q1 2028, funding ARC-IM® development (40%), ARC-EX® commercialization (30%), and operational scaling (30%).
- New shares will list on Euronext Brussels, Amsterdam, and Paris on April 20, 2026.
The big picture
ONWARD Medical’s €40.6M raise underscores investor confidence in neurotechnology solutions for spinal cord injuries, particularly as the ARC-IM® system moves toward pivotal trials. The funding aligns with broader trends in medical innovation, where implantable and AI-driven therapies are gaining traction. With a cash runway extending into 2028, ONWARD can now focus on commercializing ARC-EX® while advancing ARC-IM®, positioning itself as a leader in restoring movement for patients with disabilities.
What we're watching
- Clinical Progress
- The pace at which ARC-IM® advances through the Empower BP pivotal trial will determine its regulatory and commercial viability.
- Commercial Execution
- Whether ONWARD can scale ARC-EX® sales in the US and Europe while managing operational costs will shape its path to profitability.
- Investor Confidence
- How the 90-day lock-up period impacts share price volatility and investor sentiment post-listing.
Related topics